文献速递前列腺癌

F-SHARP:针对放射性复发前列腺癌的局灶挽救性高剂量率近距离放疗的I/II期试验

F-SHARP: a Phase I/II trial of focal salvage high-dose-rate brachytherapy for Radiorecurrent prostate cancer.
PubMed 文献 · BJU Int · 2023-09-15

F-SHARP是一项多机构两阶段I/II期临床试验,旨在评估局灶挽救性高剂量率近距离放疗治疗放射性复发前列腺癌的急性和晚期毒性及疗效。主要终点为近距离放疗后3个月内急性放射相关≥3级泌尿生殖和胃肠道毒性发生率。研究分两阶段进行,第一阶段入组7例,若≥2例发生≥3级毒性则停止,否则再入组17例(共24例);第二阶段扩展至62例受试者。

要点

  • 主要终点是近距离放疗后3个月内急性放射相关≥3级泌尿生殖和胃肠道毒性率。
  • 第一阶段入组7例,若≥2例发生≥3级胃肠道或泌尿生殖毒性则研究停止,否则再入组17例(共24例)。
  • 第二阶段队列扩展至62例受试者,研究疗效结局、长期毒性、生活质量和比较单次与多次分割HDR。

核心结论

  • F-SHARP试验旨在确定局灶挽救性高剂量率近距离放疗治疗放射性复发前列腺癌的急性和晚期毒性及疗效结局。

研究设计与样本

  • F-SHARP是一项多机构两阶段I/II期临床试验,在三个中心入组患者。
  • 第一阶段入组7例患者,若发生≥2例胃肠道或泌尿生殖≥3级毒性则研究停止,否则再入组17例患者(共24例)。
  • 第二阶段队列扩展至62例受试者,以研究疗效结局、长期毒性特征、生活质量,并比较单次与多次分割HDR。

关键数值与推荐

  • 关键入选标准包括:既往接受任何放疗方式的确诊放射性复发前列腺腺癌,无区域或远处转移证据,初始治疗时为cT1-3a Nx或N0前列腺癌。
  • 所有患者将尽可能接受多参数磁共振成像和分子PET/CT成像。
  • 主要终点为近距离放疗后3个月内急性放射相关≥3级常见不良事件术语标准(CTCAE,版本4.03)泌尿生殖和胃肠道毒性率。
  • 次要终点包括急性和晚期CTCAE毒性、生化失败、临床进展模式、疾病特异性和总生存,以及通过国际前列腺症状评分和26项扩展前列腺癌指数综合仪器测量的健康相关生活质量。
  • 将对复发活检进行转录组分析,以识别潜在的预后和预测生物标志物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Intraprostatic local radiorecurrence (LRR) after definitive radiation is being increasingly identified due to the implementation of molecular positron emission tomography (PET)/computed tomography (CT) imaging for the evaluation of biochemical recurrence. Salvage high-dose rate (HDR) brachytherapy offers a promising local therapy option, with encouraging toxicity and efficacy based on early series. Furthermore, the incorporation of advanced imaging allows for focal HDR to further reduce toxicity to maximise the therapeutic ratio. The objectives of the 'focal salvage HDR brachytherapy for locally recurrent prostate cancer in patients treated with prior radiotherapy' (F-SHARP) trial are to determine the acute and late toxicity and efficacy outcomes of focal salvage HDR brachytherapy for LRR prostate cancer. STUDY DESIGN: The F-SHARP is a multi-institutional two-stage Phase I/II clinical trial of salvage focal HDR brachytherapy for LRR prostate cancer enrolling patients at three centres. ENDPOINTS: The primary endpoint is the acute radiation-related Grade ≥3 Common Terminology Criteria for Adverse Events (CTCAE, version 4.03) genitourinary (GU) and gastrointestinal (GI) toxicity rate, defined as within 3 months of brachytherapy. Secondary endpoints include acute and late CTCAE toxicity, biochemical failure, patterns of clinical progression, disease-specific and overall survival, and health-related quality of life, as measured by the International Prostate Symptom Score and 26-item Expanded Prostate Cancer Index Composite instruments. PATIENTS AND METHODS: Key eligibility criteria include: biopsy confirmed LRR prostate adenocarcinoma after prior definitive radiation therapy using any radiotherapeutic modality, no evidence of regional or distant metastasis, and cT1-3a Nx or N0 prostate cancer at initial treatment. All patients will have multiparametric magnetic resonance imaging and molecular PET/CT imaging if possible. In Stage 1, seven patients will be accrued. If there are two or more GI or GU Grade ≥3 toxicities, the study will be stopped. Otherwise, 17 additional patients will be accrued (total of 24 patients). For Stage 2, the cohort will expand to 62 subjects to study the efficacy outcomes, long-term toxicity profile, quality of life, and compare single- vs multi-fraction HDR. Transcriptomic analysis of recurrence biopsies will be performed to identify potential prognostic and predictive biomarkers.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Solanki AA, Yoo RK, Adams W, et al. F-SHARP: a Phase I/II trial of focal salvage high-dose-rate brachytherapy for Radiorecurrent prostate cancer. BJU Int. 2023. PMID: 37562825. doi:10.1111/bju.16150

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。